

### **Clinical Review**

## Psoriasis and its management

BMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7564.380 (Published 17 August 2006)

Cite this as: BMJ 2006;333:380



Catherine H Smith (catherine.smith@kcl.ac.uk), consultant dermatologist1, J N W N Barker, professor of clinical dermatology1

### Author affiliations >

Correspondence to: C H Smith

Accepted 30 June 2006

### Introduction

Behcet (1935) referred to the highly stigmatising and common inflammatory skin disease psoriasis (derived from the Greek word psora meaning itch) as "the antidote to a dermatologist's ego," and although in some respects this is still true, major progress has been made in several important areas. Psoriasis occurs worldwide and affects about 2% of the population in the United Kingdom.

A great deal is known about the genetic and immunological mechanisms underlying the pathogenesis of psoriasis. Some of the new biological treatments recently licensed for psoriasis have been developed as a result of this improved understanding, whereas others have been contributory—for example, the profound efficacy of agents that block the actions of cytokine tumour necrosis factor highlighted the key role of tumour necrosis factor in the disease's pathogenesis. Evidence is also accumulating that psoriasis is not just associated with skin disease. Epidemiological studies have shown an increased standardised mortality in patients with psoriasis, particularly related to cancer and heart disease. Clinically relevant psychological and psychiatric comorbidity are also common and potentially amenable to therapeutic intervention. This article presents an overview of these developments and their implications for clinical practice.

### What causes psoriasis?

### **Genetic factors**

Scans of the human genome reveal at least nine different loci with susceptibility to psoriasis (PSORS1-9). PSORS-1, a region of the major histocompatibility complex on chromosome 6p2, is the major genetic determinant of psoriasis, and accounts for up to 50% of genetic susceptibility to the disease,<sup>1</sup> w<sup>1</sup> although the definitive gene has not yet been identified.

Several of the implicated loci are shared by other autoimmune and inflammatory diseases such as inflammatory bowel disease, type1 diabetes, multiple sclerosis, and atopic dermatitis, suggesting that similar mechanisms underlie many common genetically complex inflammatory diseases.

### **Summary points**

Psoriasis is a common, disfiguring, and stigmatising skin disease associated with profound impaired quality of life

The gene ...

### View Full Text

## Log in

BMA Member Log In
If you have a subscription to The BMJ, log in:
Username
Password
Forgot your log in details?
Login
Need to activate
Log in via institution 🕝
Log in via OpenAthens ☑
Subscribe from £184 *

Subscribe and get access to all BMJ articles, and much more.

### Subscribe

\* For online subscription


# Access this article for 1 day for:

£33 / \$40 / €36 (excludes VAT)


You can download a PDF version for your personal record.


Buy this article












## Back to top



Policies
Submit your paper

### Resources

Authors

Reviewers

BMA members

Readers

Subscribers

Advertisers and sponsors

Media

Recruiters

# **Explore BMJ**

Our company

**BMJ Careers** 

BMJ Learning

BMJ Masterclasses

BMJ Journals

**BMJ Student** 

Academic edition of The BMJ

**BMJ Best Practice** 

The BMJ Awards

## My account

Email alerts

Activate subscription

### Information

Contact us

Complaints

Cookie settings | Cookie Policy | Privacy policy | Website T&Cs | Revenue Sources | HighWire Press Sitemap

Copyright © 2024 BMJ Publishing Group Ltd